Grainne M. O'Kane
Princess Margaret Cancer Centre
114 Papers
104 Citations
Grainne M. O'Kane is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 18, co-authored 60 publications. Previous affiliations of Grainne M. O'Kane include Ontario Institute for Cancer Research & Toronto General Hospital.
Chat about Author
Papers
Organoid profiling identifies common responders to chemotherapy in pancreatic cancer
Hervé Tiriac,Pascal Belleau,Dannielle D. Engle,Dennis Plenker,Astrid Deschênes,Tim D.D. Somerville,Fieke E. M. Froeling,Richard A. Burkhart,Robert E. Denroche,Gun-Ho Jang,Koji Miyabayashi,C. Megan Young,C. Megan Young,Hardik Patel,Michelle Ma,Joseph F. LaComb,Randze Lerie Palmaira,Ammar A. Javed,Jasmine Huynh,Molly E. Johnson,Kanika Arora,Nicolas Robine,Minita Shah,Rashesh Sanghvi,Austin Goetz,Cinthya Y. Lowder,Laura A. Martello,Else Driehuis,Nicolas Lecomte,Gokce Askan,Christine A. Iacobuzio-Donahue,Hans Clevers,Laura D. Wood,Ralph H. Hruban,Elizabeth D. Thompson,Andrew J. Aguirre,Brian M. Wolpin,Aaron R. Sasson,Joseph Kim,Maoxin Wu,Juan Carlos Bucobo,Peter J. Allen,Divyesh V. Sejpal,William Nealon,James Sullivan,Jordan M. Winter,Phyllis A. Gimotty,Jean L. Grem,Dominick J. DiMaio,Jonathan M. Buscaglia,Paul M. Grandgenett,Jonathan R. Brody,Michael A. Hollingsworth,Grainne M. O'Kane,Faiyaz Notta,Edward J. Kim,James M. Crawford,Craig Devoe,Allyson J. Ocean,Christopher L. Wolfgang,Kenneth H. Yu,Ellen Li,Christopher R. Vakoc,Benjamin Hubert,Sandra Fischer,Sandra Fischer,Julie M. Wilson,Richard A. Moffitt,Jennifer J. Knox,Alexander Krasnitz,Steven Gallinger,Steven Gallinger,Steven Gallinger,David A. Tuveson +73 more
TL;DR: A pancreatic cancer patient-derived organoid (PDO) library is generated that recapitulates the mutational spectrum and transcriptional subtypes of primary Pancreatic cancer and proposes that combined molecular and therapeutic profiling of PDOs may predict clinical response and enable prospective therapeutic selection.
Sensitive tumour detection and classification using plasma cell-free DNA methylomes
Shu Yi Shen,Rajat Singhania,Gordon Fehringer,Ankur Chakravarthy,Michael H.A. Roehrl,Michael H.A. Roehrl,Michael H.A. Roehrl,Dianne Chadwick,Philip C. Zuzarte,Ayelet Borgida,Ting Ting Wang,Ting Ting Wang,Tiantian Li,Olena Kis,Zhen Zhao,Anna Spreafico,Tiago Medina,Yadon Wang,David Roulois,David Roulois,Ilias Ettayebi,Ilias Ettayebi,Zhuo Chen,Signy Chow,Tracy Murphy,Andrea Arruda,Grainne M. O'Kane,Jessica Liu,Mark Mansour,John Douglas Mcpherson,Catherine A. O’Brien,Natasha B. Leighl,Philippe L. Bedard,Neil E. Fleshner,Geoffrey Liu,Geoffrey Liu,Mark D. Minden,Steven Gallinger,Steven Gallinger,Anna Goldenberg,Trevor J. Pugh,Trevor J. Pugh,Michael M. Hoffman,Michael M. Hoffman,Scott V. Bratman,Scott V. Bratman,Rayjean J. Hung,Rayjean J. Hung,Daniel D. De Carvalho,Daniel D. De Carvalho +49 more
TL;DR: An immunoprecipitation-based protocol is developed to analyse DNA methylation in small quantities of circulating cell-free DNA, and can detect and classify cancers in plasma samples from several tumour types.
Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial
Kyaw L. Aung,Sandra Fischer,Sandra Fischer,Robert E. Denroche,Gun-Ho Jang,Anna Dodd,Sean Creighton,Bernadette Southwood,Sheng-Ben Liang,Dianne Chadwick,Amy Zhang,Grainne M. O'Kane,Hamzeh Albaba,Shari Moura,Robert C. Grant,Jessica Miller,Faridah Mbabaali,Danielle Pasternack,Ilinca Lungu,John M. S. Bartlett,Sangeet Ghai,Mathieu Lemire,Spring Holter,Ashton A. Connor,Richard A. Moffitt,Richard A. Moffitt,Jen Jen Yeh,Lee Timms,Paul M. Krzyzanowski,Neesha C. Dhani,David W. Hedley,Faiyaz Notta,Julie M. Wilson,Malcolm J. Moore,Steven Gallinger,Jennifer J. Knox +35 more
TL;DR: Prospective genomic profiling of advanced PDAC is feasible, and early data indicate that chemotherapy response differs among patients with different genomic/transcriptomic subtypes.
Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution
Michelle Chan-Seng-Yue,Michelle Chan-Seng-Yue,J. Kim,J. Kim,Gavin W. Wilson,Karen Ng,Eugenia Flores Figueroa,Grainne M. O'Kane,Grainne M. O'Kane,Ashton A. Connor,Robert E. Denroche,Robert C. Grant,Jessica McLeod,Julie M. Wilson,Gun Ho Jang,Amy Zhang,Anna Dodd,Sheng-Ben Liang,Ayelet Borgida,Dianne Chadwick,Sangeetha N Kalimuthu,Ilinca Lungu,John M. S. Bartlett,Paul M. Krzyzanowski,Vandana Sandhu,Hervé Tiriac,Hervé Tiriac,Hervé Tiriac,Fieke E. M. Froeling,Fieke E. M. Froeling,Fieke E. M. Froeling,Joanna M. Karasinska,James T. Topham,Daniel J. Renouf,David F. Schaeffer,Steven J.M. Jones,Marco A. Marra,Janessa Laskin,Runjan Chetty,Lincoln Stein,Lincoln Stein,George Zogopoulos,George Zogopoulos,Benjamin Haibe-Kains,Peter J. Campbell,Peter J. Campbell,David A. Tuveson,David A. Tuveson,Jennifer J. Knox,Jennifer J. Knox,Sandra Fischer,Sandra Fischer,Steven Gallinger,Faiyaz Notta,Faiyaz Notta,Faiyaz Notta +55 more
TL;DR: Whole-genome sequencing, transcriptome sequencing and single-cell analysis of primary and metastatic pancreatic adenocarcinoma identify molecular subtypes and intratumor heterogeneity, and support the premise that the constellation of genomic aberrations in the tumor gives rise to the molecular subtype.
513
Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity.
Kebria Hezaveh,Rahul S. Shinde,Andreas Klötgen,Marie Jo Halaby,S. Lamorte,M. Teresa Ciudad,Rene Quevedo,Luke Neufeld,Zhe Liu,Robbie Jin,Barbara Grünwald,Elisabeth G. Foerster,Danica Chaharlangi,Mengdi Guo,Priya Makhijani,Xin Zhang,Trevor J. Pugh,Devanand M. Pinto,Ileana L. Co,Alison P. McGuigan,Gun Ho Jang,Rama Khokha,Pamela S. Ohashi,Grainne M. O'Kane,Steven Gallinger,William Wiley Navarre,Heather Maughan,Dana J. Philpott,David J. Brooks,Tracy L. McGaha +29 more
TL;DR: In this article , the authors examined the impact of the aryl hydrocarbon receptor (AhR) in tumor-associated macrophage (TAM) function in pancreatic ductal adenocarcinoma (PDAC).
388